"Dipyridamole" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
| Descriptor ID |
D004176
|
| MeSH Number(s) |
D03.383.742.175
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dipyridamole".
Below are MeSH descriptors whose meaning is more specific than "Dipyridamole".
This graph shows the total number of publications written about "Dipyridamole" by people in this website by year, and whether "Dipyridamole" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dipyridamole" by people in Profiles.
-
Barlas RS, Loke YK, Mamas MA, Bettencourt-Silva JH, Ford I, Clark AB, Bowles KM, Metcalf AK, Potter JF, Myint PK. Effect of Antiplatelet Therapy (Aspirin?+?Dipyridamole Versus Clopidogrel) on Mortality Outcome in Ischemic Stroke. Am J Cardiol. 2018 09 15; 122(6):1085-1090.
-
Fenimore GS. Evaluating CAD with a pharmacologic stress test. Nursing. 2010 May; 40(5):51-2.
-
Usman MH, Notaro LA, Nagarakanti R, Brahin E, Dessain S, Gracely E, Ezekowitz MD. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Am J Cardiol. 2009 Apr 15; 103(8):1107-12.
-
Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Sacco RL, Schwamm LH. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008 May; 39(5):1647-52.
-
Landolfi R, Di Gennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica. 2008 Mar; 93(3):331-5.
-
Jamieson DG, Parekh A, Ezekowitz MD. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents. J Cardiovasc Pharmacol Ther. 2005 Sep; 10(3):153-61.
-
Chakravarthy A, Abrams RA, Yeo CJ, Korman LT, Donehower RC, Hruban RH, Zahurek ML, Grochow LB, O'Reilly S, Hurwitz H, Jaffee EM, Lillemoe KD, Cameron JL. Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. Int J Radiat Oncol Biol Phys. 2000 Nov 01; 48(4):1089-96.
-
Berti E, Carrara M, Ragazzi E, D'Ancona S, Berti T. A comparison of the modulation of antiblastics cytotoxicity by verapamil and dipyridamole in a human colon carcinoma cell line. Int J Oncol. 1999 Jul; 15(1):155-60.
-
D'Ancona S, Ragazzi E, Fassina G, Mazzo M, Gusella M, Berti T. Effect of dipyridamole, 5'-(N-ethyl)-carboxamidoadenosine and 1,3-dipropyl-8-(2-amino-4-chlorophenyl)-xanthine on LOVO cell growth and morphology. Anticancer Res. 1994 Jan-Feb; 14(1A):93-7.
-
Tse KK, Alavi A, Eisen HJ. Noninvasive diagnosis of cardiac transplant arteriopathy with dipyridamole thallium scintigraphy. J Nucl Med. 1993 Nov; 34(11):2049-52.